Guizhou Bailing Group Pharmaceutical (002424.SZ): Approval received for clinical trials of Tangning Tongluo tablets.

Guizhou Bailing Group Pharmaceutical (002424.SZ) announced that its wholly-owned subsidiary, Bailin Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. ("Bailin Yuxiu"), has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA). The clinical trial application for Tangning Tongluo Tablets submitted by Bailin Yuxiu has been approved, allowing the product to conduct Phase III clinical trials for diabetic retinopathy.